Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

SOPHiA Myeloid Plus Solution

Laboratory Developed Test
Related tests:


SOPHiA Myeloid Plus Solution is a ready-to-use genomic application that enables accurate characterization of DNA and RNA-based fusions associated with different blood cancers. This comprehensive solution accurately covers 30 genes already covered in the SOPHiA Myeloid Solution and 119 RNA-based fusions associated with myelodysplastic syndromes, myeloproliferative neoplasms, and leukemia. The application combines a capture-based target enrichment kit with the advanced analytical capabilities of the SOPHiA DDM™ platform, providing high-quality and reproducible data through a streamlined workflow from sample to report.​ Through a streamlined, customizable, and scalable NGS-based workflow, SOPHiA Myeloid Plus Solution reduces turnaround time and improves the efficiency of assessing complex variants associated with different blood cancers.
Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm
ABL1 (ABL proto-oncogene 1), ASXL1 (ASXL Transcriptional Regulator 1), BRAF (B-raf proto-oncogene), CALR (Calreticulin), CBL (Cbl proto-oncogene), CEBPA (CCAAT Enhancer Binding Protein Alpha)
See More ...
Next-Generation Sequencing (NGS)